Eu­ro­pean in­vestors pour $156M to beat Blue­stone, Third Rock and RA Cap­i­tal in multi­bil­lion-dol­lar race to the clin­ic

Amid bur­geon­ing ef­forts to cre­ate a new type of cell ther­a­py out of reg­u­la­to­ry T cells — whether by chan­nel­ing or block­ing their im­muno­sup­pres­sive pow­er — Quell Ther­a­peu­tics wants to shoot for a first.

If every­thing goes well, the Syn­cona-backed biotech will be in the clin­ic ear­ly next year, mark­ing what it calls the his­toric feat of dos­ing a pa­tient with a CAR-Treg with mul­ti­ple edit­ed genes.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER